Bellerophon Therapeutics, Inc. (BLPH)

Bellerophon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selling, General & Admin	6.97	6.02	7.15	8.39	6.44	7.62
Research & Development	9.71	16.37	12.6	17.89	11.03	20.26
Operating Expenses	16.68	22.39	19.75	26.28	17.47	27.88
Operating Income	-11.04	-22.39	-19.75	-26.28	-17.47	-27.88
Interest Expense	-	-	-	-0.25	-	-
Interest & Investment Income	0.37	0.14	0.01	-	0.4	0.38
Other Non Operating Income (Expenses)	0	0	0.6	-0.33	2.01	24.88
EBT Excluding Unusual Items	-10.68	-22.25	-19.15	-26.85	-15.07	-2.63
Other Unusual Items	0.01	0.01	-0.41	-	-	-
Pretax Income	-10.53	-22.25	-19.56	-26.85	-15.07	-2.63
Income Tax Expense	-1.28	-2.42	-1.8	-2.13	-1.8	-5.44
Net Income	-9.25	-19.83	-17.76	-24.73	-13.27	2.81
Net Income to Common	-9.25	-19.83	-17.76	-24.73	-13.27	2.81
Shares Outstanding (Basic)	11	10	10	8	5	4
Shares Outstanding (Diluted)	11	10	10	8	5	4
Shares Change (YoY)	16.43%	0.51%	21.88%	73.14%	3.85%	67.00%
EPS (Basic)	-0.83	-2.08	-1.87	-3.17	-2.95	0.73
EPS (Diluted)	-0.83	-2.08	-1.87	-3.17	-2.95	-5.07
Free Cash Flow	-12.34	-17.77	-22.82	-19.88	-12.94	-15.5
Free Cash Flow Per Share	-1.11	-1.86	-2.40	-2.55	-2.87	-3.57
EBITDA	-11.04	-22.32	-19.65	-26.13	-17.13	-27.52
D&A For EBITDA	0.01	0.07	0.1	0.15	0.35	0.36
EBIT	-11.04	-22.39	-19.75	-26.28	-17.47	-27.88

Source: S&P Capital IQ. Standard template. Financial Sources.